 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5515 News |  |
| «12...58596061626364656667686970» |
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) (clinicaltrials.gov) - Jun 20, 2016
P3, N=452, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2015 --> May 2015
- ganetespib (ADX-1612) / Aldeyra, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (clinicaltrials.gov) - Jun 10, 2016
P1, N=18, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jan 2015 --> May 2015 Trial primary completion date: May 2016 --> Jun 2017
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Trial termination, Metastases: PETRA: Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) (clinicaltrials.gov) - Jun 10, 2016
P1, N=3, Terminated, Sponsor: Ontario Clinical Oncology Group (OCOG)
Trial primary completion date: May 2016 --> Jun 2017 N=30 --> 3 | Recruiting --> Terminated; Accrual is very poor
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer (clinicaltrials.gov) - Jun 5, 2016
P4, N=52, Recruiting, Sponsor: Hoffmann-La Roche
N=30 --> 3 | Recruiting --> Terminated; Accrual is very poor Trial primary completion date: Apr 2017 --> Apr 2019
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: BrUOG 308: Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. (clinicaltrials.gov) - Jun 4, 2016
P2, N=30, Not yet recruiting, Sponsor: William Sikov
- |||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: JACOB: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (clinicaltrials.gov) - Jun 2, 2016
P3, N=780, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Apr 2017 --> Apr 2019 Active, not recruiting --> Recruiting
- |||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: PETRARCA: FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (clinicaltrials.gov) - Jun 2, 2016
P2/3, N=404, Recruiting, Sponsor: Krankenhaus Nordwest
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib (clinicaltrials.gov) - May 12, 2016
P0, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2017 --> Dec 2016
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche
Trial primary completion date, Combination therapy: A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies (clinicaltrials.gov) - May 6, 2016
P2, N=500, Enrolling by invitation, Sponsor: Genentech, Inc.
Trial primary completion date: Mar 2017 --> Dec 2016 Trial primary completion date: Mar 2018 --> Sep 2022
- |||| Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer (clinicaltrials.gov) - May 5, 2016
P3, N=400, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2018 --> Sep 2022 Trial primary completion date: Nov 2018 --> Feb 2019
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Apr 22, 2016
P2, N=32, Active, not recruiting, Sponsor: Midwestern Regional Medical Center
Trial primary completion date: Nov 2018 --> Feb 2019 Not yet recruiting --> Active, not recruiting
- Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Trial primary completion date: SOLTI-Opti-HER: Study of Neoadjuvant Myocet (clinicaltrials.gov) - Apr 22, 2016
P2, N=83, Completed, Sponsor: SOLTI Breast Cancer Research Group
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jan 2016
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: JACOB: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (clinicaltrials.gov) - Apr 19, 2016
P3, N=780, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jan 2016 Recruiting --> Active, not recruiting
- |||| Enrollment open, Trial initiation date, PARP Biomarker: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (clinicaltrials.gov) - Apr 19, 2016
P2, N=200, Recruiting, Sponsor: Haukeland University Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Apr 2016
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer (clinicaltrials.gov) - Apr 14, 2016
P2, N=64, Recruiting, Sponsor: Lajos Pusztai
Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Apr 2016 Trial primary completion date: Jul 2016 --> Dec 2016
- Ibrance (palbociclib) / Pfizer
Enrollment closed: NA-PHER2: "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment " (clinicaltrials.gov) - Apr 8, 2016
P2, N=36, Active, not recruiting, Sponsor: Fondazione Michelangelo
Trial primary completion date: Jul 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer (clinicaltrials.gov) - Apr 6, 2016
P4, N=52, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2018 --> Apr 2017
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Metastases: PerFECT: Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients (clinicaltrials.gov) - Apr 1, 2016
P=N/A, N=300, Recruiting, Sponsor: University Hospital Tuebingen
Trial primary completion date: Sep 2018 --> Apr 2017 Not yet recruiting --> Recruiting
- ||| Enrollment closed: MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (clinicaltrials.gov) - Mar 29, 2016
P4, N=226, Active, not recruiting, Sponsor: Agendia
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Enrollment open, Tumor mutational burden, BRCA Biomarker, MSi-H Biomarker, PARP Biomarker, PD(L)-1 Biomarker, Metastases: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (clinicaltrials.gov) - Mar 26, 2016
P2, N=730, Recruiting, Sponsor: American Society of Clinical Oncology
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Trial termination, Combination therapy, Metastases: 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. (clinicaltrials.gov) - Mar 4, 2016
P2, N=2, Terminated, Sponsor: Katherine Tkaczuk
Not yet recruiting --> Recruiting N=60 --> 2 | Recruiting --> Terminated; funding withdrawn by sponsor
- | carboplatin / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Metastases: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 2, 2016
P3, N=312, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=60 --> 2 | Recruiting --> Terminated; funding withdrawn by sponsor Recruiting --> Active, not recruiting
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: PERUSE: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (clinicaltrials.gov) - Mar 2, 2016
P3, N=1432, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Surgery, Metastases: PEONY: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel (clinicaltrials.gov) - Mar 2, 2016
P3, N=328, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Perjeta (pertuzumab) / Roche
Trial completion: A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study (clinicaltrials.gov) - Feb 27, 2016
P2, N=3, Completed, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- |||| Perjeta (pertuzumab) / Roche
Trial completion, Metastases: A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer (clinicaltrials.gov) - Feb 27, 2016
P2, N=129, Completed, Sponsor: Genentech, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- | Perjeta (pertuzumab) / Roche
Trial completion: Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Feb 27, 2016
P2, N=42, Completed, Sponsor: Genentech, Inc.
No longer recruiting --> Completed Terminated --> Completed
- Herceptin (trastuzumab) / Roche
Enrollment closed, Enrollment change: A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS (clinicaltrials.gov) - Feb 26, 2016
P1/2, N=5, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Terminated --> Completed Recruiting --> Active, not recruiting | N=15 --> 5
- ||||| New P2 trial, Tumor mutational burden, BRCA Biomarker, MSi-H Biomarker, PARP Biomarker, PD(L)-1 Biomarker, Metastases: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (clinicaltrials.gov) - Feb 26, 2016
P2, N=680, Not yet recruiting, Sponsor: American Society of Clinical Oncology
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Feb 24, 2016
P2, N=32, Not yet recruiting, Sponsor: Midwestern Regional Medical Center
- |||| Perjeta (pertuzumab) / Roche
Trial primary completion date: Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (clinicaltrials.gov) - Feb 10, 2016
P3, N=1200, Active, not recruiting, Sponsor: German Breast Group
Recruiting --> Active, not recruiting | N=15 --> 5 Trial primary completion date: Jul 2014 --> Dec 2018
- | Avastin (bevacizumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Metastases: Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers (clinicaltrials.gov) - Feb 5, 2016
P2, N=43, Completed, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Jul 2014 --> Dec 2018 Active, not recruiting --> Completed
- Trial primary completion date: Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (clinicaltrials.gov) - Feb 4, 2016
P2, N=20, Recruiting, Sponsor: Columbia University
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Oct 2016
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov) - Feb 3, 2016
P2, N=69, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Jan 2016 --> Jan 2017
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Feb 2, 2016
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2016 --> Jan 2017 Trial primary completion date: Mar 2017 --> Jul 2017
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: JACOB: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (clinicaltrials.gov) - Feb 2, 2016
P3, N=780, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2017 --> Jul 2017 Trial primary completion date: Sep 2021 --> Dec 2021
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: PERUSE: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (clinicaltrials.gov) - Feb 2, 2016
P3, N=1500, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2021 --> Dec 2021 Trial primary completion date: May 2018 --> Sep 2019
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Feb 2, 2016
P2, N=400, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2018 --> Sep 2019 Trial primary completion date: Aug 2020 --> Nov 2020
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Metastases: PATRICIA: A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy (clinicaltrials.gov) - Feb 2, 2016
P2, N=40, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Aug 2020 --> Nov 2020 Initiation date: Sep 2015 --> Dec 2015
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Metastases: PerFECT: Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=300, Not yet recruiting, Sponsor: University Hospital Tuebingen
Initiation date: Sep 2015 --> Dec 2015 N=3000 --> 300
- Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: PERNETTA: Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (clinicaltrials.gov) - Jan 26, 2016
P2, N=208, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
N=3000 --> 300 Recruiting --> Active, not recruiting
- || Verzenio (abemaciclib) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Jan 26, 2016
P1, N=102, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (clinicaltrials.gov) - Jan 22, 2016
P3, N=437, Active, not recruiting, Sponsor: The Netherlands Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Perjeta (pertuzumab) / Roche
Enrollment open, Metastases: PRECIOUS: A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Jan 21, 2016
P3, N=370, Recruiting, Sponsor: Japan Breast Cancer Research Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Jan 4, 2016
P2, N=400, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, IO biomarker, Metastases: Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - Dec 31, 2015
P1, N=36, Recruiting, Sponsor: Pravin Kaumaya
Active, not recruiting --> Recruiting Trial primary completion date: Jan 2016 --> Jan 2017
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New trial, Metastases: PerFECT: Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients (clinicaltrials.gov) - Dec 30, 2015
P=N/A, N=3000, Not yet recruiting, Sponsor: University Hospital Tuebingen
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial: BOLD-1: Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer (clinicaltrials.gov) - Dec 10, 2015
P3, N=1366, Recruiting, Sponsor: Helsinki University Central Hospital
- ||||| New P2 trial, PARP Biomarker: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (clinicaltrials.gov) - Dec 10, 2015
P2, N=200, Not yet recruiting, Sponsor: Haukeland University Hospital
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer (clinicaltrials.gov) - Dec 9, 2015
P1/2, N=46, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Jan 2016 --> Jan 2017 Trial primary completion date: Mar 2016 --> Oct 2016